Your New Fundraising Playbook

In the Ophthalmic Deals Report, Market Scope analyzes recent investments in ophthalmology and introduce companies of all stages to a network of nearly 500 potential investors and their ophthalmic investment history, enabling them to raise capital and take ophthalmic ventures to the next level.

These quarterly subscription-based reports cover recent investments in ophthalmic ventures, including venture capital, public offerings, licensing, milestone payments, sales of products and companies, and major borrowings. 

These are designed for entrepreneurs, investors, venture capitalists, and companies looking to invest in the ophthalmic market—and companies looking to raise funds.

Transactions raised are categorized by fund use, including new ventures, commercial equity, sale of companies, and license payments. Four investment types are analyzed in this report: strategic investors, venture capital, public offerings, and private equity.

A detailed transaction analysis is provided for seven ophthalmic sectors: dry eye, retina, glaucoma, cataract, diagnostic, cornea, and refractive. Key investors and transactions in each sector are included. Deal counts and transaction totals are included for each ophthalmic sector.

Ophthalmic Deals Report

Q2, 2024

The “Ophthalmic Deals Report” analyzes recent investments in ophthalmology and provides information for evaluation of the market value of various technologies, as evidenced by investment amounts and sales prices for new ophthalmic ventures.

This report covers recent investments in ophthalmic ventures, including venture capital, public offerings, licensing, milestone payments, sales of products and companies, and major borrowings. The report is designed for entrepreneurs, investors, venture capitalists, and companies looking to invest in the ophthalmic market—and companies looking to raise funds.

Want to Purchase the Full Report?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more